Global Longlife Hospital And Research Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Global Longlife Hospital and Research Ltd is ₹ 12.82 as of 30 Oct 15:30 . The P/E Ratio of Global Longlife Hospital and Research Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Global Longlife Hospital and Research Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Global Longlife Hospital and Research Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57% The Dividend Payout of Global Longlife Hospital and Research Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Global Longlife Hospital and Research Ltd

Global Longlife Hospital and Research Limited was originally incorporated as 'Global Longlife Hospital and Research Private Limited' on January 20, 2012 with Registrar of Companies, Gujarat.
Subsequently, Company was converted into a Public Limited Company and , name of the Company was changed to 'Global Longlife Hospital and Research Limited' vide fresh Certificate of Incorporation dated August 31, 2021. The Company had acquired 1339 sq.mt. area land in the prime locality of Ahmedabad for starting hospital in March 2012.
The Hospital started journey in 2015 & determined to build an institution in Ahmedabad.
Mr. Dhruv Jani had also joined the hospital business with his father in July 2015.
The majority Equity shares of the Company were taken over by the present Promoters by acquiring the Equity shares from the Doctors and investors in the year 2017.

About Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC. Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care. The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.

FAQs for the comparison of Global Longlife Hospital and Research Ltd and Yatharth Hospital & Trauma Care Services Ltd

Which company has a larger market capitalization, Global Longlife Hospital and Research Ltd or Yatharth Hospital & Trauma Care Services Ltd?

Market cap of Global Longlife Hospital and Research Ltd is 13 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,942 Cr

What are the key factors driving the stock performance of Global Longlife Hospital and Research Ltd and Yatharth Hospital & Trauma Care Services Ltd?

The stock performance of Global Longlife Hospital and Research Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Global Longlife Hospital and Research Ltd and Yatharth Hospital & Trauma Care Services Ltd?

As of November 1, 2026, the Global Longlife Hospital and Research Ltd stock price is INR ₹12.82. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹928.05.

How do dividend payouts of Global Longlife Hospital and Research Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?

To compare the dividend payouts of Global Longlife Hospital and Research Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.